176 related articles for article (PubMed ID: 23856527)
41. Adenosine A2A receptor agonists inhibit lipopolysaccharide-induced production of tumor necrosis factor-alpha by equine monocytes.
Sun WC; Moore JN; Hurley DJ; Vandenplas ML; Linden J; Cao Z; Murray TF
Vet Immunol Immunopathol; 2008 Jan; 121(1-2):91-100. PubMed ID: 17913243
[TBL] [Abstract][Full Text] [Related]
42. Targeting adenosine A
Congreve M; Brown GA; Borodovsky A; Lamb ML
Expert Opin Drug Discov; 2018 Nov; 13(11):997-1003. PubMed ID: 30336706
[TBL] [Abstract][Full Text] [Related]
43. Role of adenosine A2b receptor overexpression in tumor progression.
Sepúlveda C; Palomo I; Fuentes E
Life Sci; 2016 Dec; 166():92-99. PubMed ID: 27729268
[TBL] [Abstract][Full Text] [Related]
44. Therapeutic Opportunities for Caffeine and A2A Receptor Antagonists in Retinal Diseases.
Boia R; Ambrósio AF; Santiago AR
Ophthalmic Res; 2016; 55(4):212-8. PubMed ID: 26959995
[TBL] [Abstract][Full Text] [Related]
45. A binding kinetics study of human adenosine A
Xia L; Kyrizaki A; Tosh DK; van Duijl TT; Roorda JC; Jacobson KA; IJzerman AP; Heitman LH
Biochem Pharmacol; 2018 Jul; 153():248-259. PubMed ID: 29305857
[TBL] [Abstract][Full Text] [Related]
46. Intraocular implants loaded with A
Boia R; Dias PAN; Galindo-Romero C; Ferreira H; Aires ID; Vidal-Sanz M; Agudo-Barriuso M; Bernardes R; Santos PF; de Sousa HC; Ambrósio AF; Braga MEM; Santiago AR
J Control Release; 2022 Mar; 343():469-481. PubMed ID: 35131370
[TBL] [Abstract][Full Text] [Related]
47. Thio-Cl-IB-MECA, a novel A₃ adenosine receptor agonist, suppresses angiogenesis by regulating PI3K/AKT/mTOR and ERK signaling in endothelial cells.
Kim GD; Oh J; Jeong LS; Lee SK
Biochem Biophys Res Commun; 2013 Jul; 437(1):79-86. PubMed ID: 23791876
[TBL] [Abstract][Full Text] [Related]
48. Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications.
Baraldi PG; Preti D; Borea PA; Varani K
J Med Chem; 2012 Jun; 55(12):5676-703. PubMed ID: 22468757
[No Abstract] [Full Text] [Related]
49. Gene regulation in activated microglia by adenosine A
Lillo A; Serrano-Marín J; Lillo J; Raïch I; Navarro G; Franco R
Purinergic Signal; 2024 Jun; 20(3):237-245. PubMed ID: 36703008
[TBL] [Abstract][Full Text] [Related]
50. Potential therapeutic relevance of adenosine A2B and A2A receptors in the central nervous system.
Popoli P; Pepponi R
CNS Neurol Disord Drug Targets; 2012 Sep; 11(6):664-74. PubMed ID: 22963436
[TBL] [Abstract][Full Text] [Related]
51. Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice.
Smith KM; Browne SE; Jayaraman S; Bleickardt CJ; Hodge LM; Lis E; Yao L; Rittle SL; Innocent N; Mullins DE; Boykow G; Reynolds IJ; Hill D; Parker EM; Hodgson RA
Eur J Pharmacol; 2014 Apr; 728():31-8. PubMed ID: 24486705
[TBL] [Abstract][Full Text] [Related]
52. Differential requirement for A2a and A3 adenosine receptors for the protective effect of inosine in vivo.
Gomez G; Sitkovsky MV
Blood; 2003 Dec; 102(13):4472-8. PubMed ID: 12947007
[TBL] [Abstract][Full Text] [Related]
53. Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model.
Iannone R; Miele L; Maiolino P; Pinto A; Morello S
Am J Cancer Res; 2014; 4(2):172-81. PubMed ID: 24660106
[TBL] [Abstract][Full Text] [Related]
54. Involvement of adenosine A2A receptors in depression and anxiety.
Yamada K; Kobayashi M; Kanda T
Int Rev Neurobiol; 2014; 119():373-93. PubMed ID: 25175973
[TBL] [Abstract][Full Text] [Related]
55. Adenosine A2A receptor as a drug discovery target.
de Lera Ruiz M; Lim YH; Zheng J
J Med Chem; 2014 May; 57(9):3623-50. PubMed ID: 24164628
[TBL] [Abstract][Full Text] [Related]
56. Cl-IB-MECA enhances TRAIL-induced apoptosis via the modulation of NF-kappaB signalling pathway in thyroid cancer cells.
Morello S; Sorrentino R; Porta A; Forte G; Popolo A; Petrella A; Pinto A
J Cell Physiol; 2009 Nov; 221(2):378-86. PubMed ID: 19562684
[TBL] [Abstract][Full Text] [Related]
57. Molecular modeling study on potent and selective adenosine A(3) receptor agonists.
Dal Ben D; Buccioni M; Lambertucci C; Marucci G; Thomas A; Volpini R; Cristalli G
Bioorg Med Chem; 2010 Nov; 18(22):7923-30. PubMed ID: 20943397
[TBL] [Abstract][Full Text] [Related]
58. Investigational A₃ adenosine receptor targeting agents.
Koscsó B; Csóka B; Pacher P; Haskó G
Expert Opin Investig Drugs; 2011 Jun; 20(6):757-68. PubMed ID: 21457061
[TBL] [Abstract][Full Text] [Related]
59. A3 Adenosine receptors mediate oligodendrocyte death and ischemic damage to optic nerve.
González-Fernández E; Sánchez-Gómez MV; Pérez-Samartín A; Arellano RO; Matute C
Glia; 2014 Feb; 62(2):199-216. PubMed ID: 24311446
[TBL] [Abstract][Full Text] [Related]
60. Discovery of a potent, selective, and tumor-suppressing antibody antagonist of adenosine A2A receptor.
Wang L; Garg P; Chan KY; Yuan TZ; Lujan Hernandez AG; Han Z; Peterson SM; Tuscano E; Safavi C; Kwan E; Villalta M; Mathur M; Lai J; Axelrod F; Souders CA; Emery C; Sato AK
PLoS One; 2024; 19(6):e0301223. PubMed ID: 38837964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
